BACKGROUND Studies have reported that microRNA-30c(miR-30c)has vital functions in the development and progression of multiple cancers.AIM To investigate the clinical significance and role of miR-30c in pancreatic canc...BACKGROUND Studies have reported that microRNA-30c(miR-30c)has vital functions in the development and progression of multiple cancers.AIM To investigate the clinical significance and role of miR-30c in pancreatic cancer.METHODS MiR-30c and twinfilin 1(TWF1)expression levels were analyzed in Gene Expression Omnibus datasets and validated in human pancreatic cancer by quantitative real-time polymerase chain reaction(RT-qPCR).The effects of miR-30c on pancreatic cancer cell growth,apoptosis,and cell cycle were evaluated by CCK-8 and flow cytometry assays.Furthermore,the in vivo effects were investigated using a subcutaneous xenograft experiment.Target gene prediction software and luciferase reporter assays were used to identify TWF1 as a direct target of miR-30c.RESULTS The expression of miR-30c was significantly decreased in pancreatic cancer tissues and associated with survival.Gain-and loss-of-function assays showed that miR-30c suppressed pancreatic cancer cell proliferation in vitro and in vivo.RT-qPCR,Western blot,and luciferase reporter assays showed that miR-30c directly targeted TWF1.The expression level of miR-30c was negatively correlated with TWF1 expression in pancreatic cancer tissues.Furthermore,the effects of ectopic miR-30c were rescued by TWF1 overexpression.CONCLUSION Our results identified the role of the miR-30c/TWF1 axis in pancreatic cancer progression and demonstrated that miR-30c might serve as a prognostic biomarker and therapeutic target for pancreatic cancer.展开更多
目的探究黄芪益肾颗粒联合腹膜透析对慢性肾衰竭(CRF)患者肾功能及血清微RNA-30a(miR-30a)、同型半胱氨酸(Hcy)、胱抑素C(Cys C)表达的影响。方法选取2017年10月—2019年12月医院112例CRF患者进行前瞻性随机对照研究,以计算机生成的随...目的探究黄芪益肾颗粒联合腹膜透析对慢性肾衰竭(CRF)患者肾功能及血清微RNA-30a(miR-30a)、同型半胱氨酸(Hcy)、胱抑素C(Cys C)表达的影响。方法选取2017年10月—2019年12月医院112例CRF患者进行前瞻性随机对照研究,以计算机生成的随机数字表将患者分为研究组(56例)、对照组(56例)。常规治疗基础上,对照组予以腹膜透析,研究组予以黄芪益肾颗粒联合腹膜透析,均连续治疗2个月。比较两组疗效、治疗前、治疗2个月后肾功能指标[血肌酐(Scr)、尿素氮(BUN)、24 h尿蛋白定量(24 h Upro)]、症状积分、血清炎症因子指标[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]、T淋巴细胞亚群指标(CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+))、miR-30a、Hcy、CysC水平。结果研究组治疗2个月后总有效率(92.86%,52/56)高于对照组(76.79%,43/56)(P<0.05);研究组治疗2个月后血清Scr、BUN及24 h Upro水平均低于对照组(P<0.05);研究组治疗2个月后倦怠乏力、腰膝酸软、夜尿、多尿、水肿、贫血积分均低于对照组(P<0.05);研究组治疗2个月后血清TNF-α、IL-6、CRP水平均低于对照组(P<0.05);研究组治疗2个月后血清CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)水平高于对照组,CD_(8)^(+)水平低于对照组(P<0.05);研究组治疗2个月后血清miR-30a、Hcy、CysC水平均低于对照组(P<0.05)。结论CRF患者腹膜透析治疗中联合应用黄芪益肾颗粒,能进一步下调血清miR-30a、Hcy、CysC表达,增强机体免疫功能,促进患者肾功能改善,减轻炎症反应及临床症状,显著提高疗效。展开更多
基金Supported by the National Nature Science Foundation of China,No.61802350
文摘BACKGROUND Studies have reported that microRNA-30c(miR-30c)has vital functions in the development and progression of multiple cancers.AIM To investigate the clinical significance and role of miR-30c in pancreatic cancer.METHODS MiR-30c and twinfilin 1(TWF1)expression levels were analyzed in Gene Expression Omnibus datasets and validated in human pancreatic cancer by quantitative real-time polymerase chain reaction(RT-qPCR).The effects of miR-30c on pancreatic cancer cell growth,apoptosis,and cell cycle were evaluated by CCK-8 and flow cytometry assays.Furthermore,the in vivo effects were investigated using a subcutaneous xenograft experiment.Target gene prediction software and luciferase reporter assays were used to identify TWF1 as a direct target of miR-30c.RESULTS The expression of miR-30c was significantly decreased in pancreatic cancer tissues and associated with survival.Gain-and loss-of-function assays showed that miR-30c suppressed pancreatic cancer cell proliferation in vitro and in vivo.RT-qPCR,Western blot,and luciferase reporter assays showed that miR-30c directly targeted TWF1.The expression level of miR-30c was negatively correlated with TWF1 expression in pancreatic cancer tissues.Furthermore,the effects of ectopic miR-30c were rescued by TWF1 overexpression.CONCLUSION Our results identified the role of the miR-30c/TWF1 axis in pancreatic cancer progression and demonstrated that miR-30c might serve as a prognostic biomarker and therapeutic target for pancreatic cancer.
文摘目的探究黄芪益肾颗粒联合腹膜透析对慢性肾衰竭(CRF)患者肾功能及血清微RNA-30a(miR-30a)、同型半胱氨酸(Hcy)、胱抑素C(Cys C)表达的影响。方法选取2017年10月—2019年12月医院112例CRF患者进行前瞻性随机对照研究,以计算机生成的随机数字表将患者分为研究组(56例)、对照组(56例)。常规治疗基础上,对照组予以腹膜透析,研究组予以黄芪益肾颗粒联合腹膜透析,均连续治疗2个月。比较两组疗效、治疗前、治疗2个月后肾功能指标[血肌酐(Scr)、尿素氮(BUN)、24 h尿蛋白定量(24 h Upro)]、症状积分、血清炎症因子指标[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]、T淋巴细胞亚群指标(CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+))、miR-30a、Hcy、CysC水平。结果研究组治疗2个月后总有效率(92.86%,52/56)高于对照组(76.79%,43/56)(P<0.05);研究组治疗2个月后血清Scr、BUN及24 h Upro水平均低于对照组(P<0.05);研究组治疗2个月后倦怠乏力、腰膝酸软、夜尿、多尿、水肿、贫血积分均低于对照组(P<0.05);研究组治疗2个月后血清TNF-α、IL-6、CRP水平均低于对照组(P<0.05);研究组治疗2个月后血清CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)水平高于对照组,CD_(8)^(+)水平低于对照组(P<0.05);研究组治疗2个月后血清miR-30a、Hcy、CysC水平均低于对照组(P<0.05)。结论CRF患者腹膜透析治疗中联合应用黄芪益肾颗粒,能进一步下调血清miR-30a、Hcy、CysC表达,增强机体免疫功能,促进患者肾功能改善,减轻炎症反应及临床症状,显著提高疗效。
